Disruption of GIP/GIPR Axis in Human Adipose Tissue Is Linked to Obesity and Insulin Resistance
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
CONTEXT: Glucose-dependent insulinotropic peptide (GIP) has a central role in glucose homeostasis through its amplification of insulin secretion; however, its physiological role in adipose tissue is unclear. OBJECTIVE: Our objective was to define the function of GIP in human adipose tissue in relation to obesity and insulin resistance. DESIGN: GIP receptor (GIPR) expression was analyzed in human sc adipose tissue (SAT) and visceral adipose (VAT) from lean and obese subjects in 3 independent cohorts. GIPR expression was associated with anthropometric and biochemical variables. GIP responsiveness on insulin sensitivity was analyzed in human adipocyte cell lines in normoxic and hypoxic environments as well as in adipose-derived stem cells obtained from lean and obese patients. RESULTS: GIPR expression was downregulated in SAT from obese patients and correlated negatively with body mass index, waist circumference, systolic blood pressure, and glucose and triglyceride levels. Furthermore, homeostasis model assessment of insulin resistance, glucose, and G protein-coupled receptor kinase 2 (GRK2) emerged as variables strongly associated with GIPR expression in SAT. Glucose uptake studies and insulin signaling in human adipocytes revealed GIP as an insulin-sensitizer incretin. Immunoprecipitation experiments suggested that GIP promotes the interaction of GRK2 with GIPR and decreases the association of GRK2 to insulin receptor substrate 1. These effects of GIP observed under normoxia were lost in human fat cells cultured in hypoxia. In support of this, GIP increased insulin sensitivity in human adipose-derived stem cells from lean patients. GIP also induced GIPR expression, which was concomitant with a downregulation of the incretin-degrading enzyme dipeptidyl peptidase 4. None of the physiological effects of GIP were detected in human fat cells obtained from an obese environment with reduced levels of GIPR. CONCLUSIONS: GIP/GIPR signaling is disrupted in insulin-resistant states, such as obesity, and normalizing this function might represent a potential therapy in the treatment of obesity-associated metabolic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Postprandial excursions of insulin drive glucose dis posal through actions in muscle and adipose tissue, along with effects of postprandial excursions in GIP, to enhance insulin sensitivity and augment glucose disposal in adipose tissue (2-5).”
From Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test (2024) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In addition, the homeostasis model assessment of IR, glucose and G protein-coupled receptor kinase 2 (GRK2) appeared as variables that were robustly linked with GIP-R expression in SAT.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [117]
The cited source says what the claim attributes to it.
In the citing paper
“Human fat cells cultured in hypoxia lacked the GIP actions reported under normoxia.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [117]
The cited source says what the claim attributes to it.
In the citing paper
“These physiological actions of GIP were not identified in human fat cells derived from an obese milieu characterized by diminished amounts of GIP-R.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [117]
The cited source says what the claim attributes to it.
In the citing paper
“In support of this, human adipose-derived stem cells from lean individuals showed increased insulin sensitivity as a result of GIP.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [117]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
G Protein–Coupled Receptor Kinase 2 Plays a Relevant Role in Insulin Resistance and Obesity
Garcia-Guerra, L., Nieto-Vazquez, I., Vila-Bedmar, R., Jurado-Pueyo, M., Zalba, G., Díez, J., Murga, C., Fernández-Veledo, S., Mayor, F., & Lorenzo, M. (2010) · Diabetes · doi:10.2337/db10-0771 · Cited by 92
RetractedAssociation analyses of 249,796 individuals reveal 18 new loci associated with body mass index
MAGIC, Speliotes, E. K., on behalf of Procardis Consortium, Willer, C. J., Berndt, S. I., Monda, K. L., Thorleifsson, G., Jackson, A. U., Allen, H. L., Lindgren, C. M., et al. (2010) · Nature Genetics · doi:10.1038/ng.686 · Cited by 2,912
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome — An allostatic perspective
Virtue, S., & Vidal-Puig, A. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.12.006 · Cited by 1,013 · cited 1×
“a causal link between obesity and insulin resistance (29).”
BackgroundInhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 5×
“E912 Ceperuelo-Mallafré et al GIP Resistance in Obesity J Clin Endocrinol Metab, May 2014, 99(5):E908–E919”
BackgroundMethodInfluentialHypoxia and Adipose Tissue Function and Dysfunction in Obesity
Trayhurn, P. (2013) · Physiological Reviews · doi:10.1152/physrev.00017.2012 · Cited by 878
Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome
Lamers, D., Famulla, S., Wronkowitz, N., Hartwig, S., Lehr, S., Ouwens, D. M., Eckardt, K., Kaufman, J. M., Ryden, M., Müller, S., et al. (2011) · Diabetes · doi:10.2337/db10-1707 · Cited by 582
Characterization of a human preadipocyte cell strain with high capacity for adipose differentiation
Wabitsch, M., Brenner, R., Melzner, I., Braun, M., Möller, P., Heinze, E., Debatin, K.-M., & Hauner, H. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801520 · Cited by 562
T., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518 · cited 1×
“ness of -cells to GIP in hyperglycemia (3).”
BackgroundMiyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454 · cited 1×
“As stated previously, the effects of GIP on insulin sensitivity is a controversial subject in the literature (12, 13, 15).”
Background
Cited by
Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Thomas, M. K., Nikooienejad, A., Bray, R., Cui, X., Wilson, J., Duffin, K., Milicevic, Z., Haupt, A., & Robins, D. A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa863 · Cited by 345
“proposed insulin-sensitizing actions of GIP on human adipocytes (28), as adiponectin is produced in adipocytes.”
BackgroundBrown Adipose Tissue—A Translational Perspective
Carpentier, A. C., Blondin, D. P., Haman, F., & Richard, D. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac015 · Cited by 198
Adipose Tissue and Metabolic Health
An, S.-M., Cho, S.-H., & Yoon, J. C. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0011 · Cited by 184
Reappraisal of GIP Pharmacology for Metabolic Diseases
Finan, B., Müller, T. D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R. D., & Tschöp, M. H. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.005 · Cited by 180
Campbell, J. E., Müller, T. D., Finan, B., DiMarchi, R. D., Tschöp, M. H., & D’Alessio, D. A. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.010 · Cited by 149
The intestine as an endocrine organ and the role of gut hormones in metabolic regulation
Bany Bakar, R., Reimann, F., & Gribble, F. M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00830-y · Cited by 144
Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects
Zhang, H., Sturchler, E., Zhu, J., Nieto, A., Cistrone, P. A., Xie, J., He, L., Yea, K., Jones, T., Turn, R., et al. (2015) · Nature Communications · doi:10.1038/ncomms9918 · Cited by 137
Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
Campbell, J. E. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101139 · Cited by 133
“Gipr/ GIPR levels are detectable in rodent [36] and human [37] white adipose”
BackgroundPachón-Peña, G., Serena, C., Ejarque, M., Petriz, J., Duran, X., Oliva-Olivera, W., Simó, R., Tinahones, F. J., Fernández-Veledo, S., & Vendrell, J. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0161 · Cited by 132
Engin, A. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-48382-5_13 · Cited by 138
Malavazos, A. E., Iacobellis, G., Dozio, E., Basilico, S., Di Vincenzo, A., Dubini, C., Menicanti, L., Vianello, E., Meregalli, C., Ruocco, C., et al. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad050 · Cited by 100
Control of insulin secretion by GLP-1
Jones, B. J., Bloom, S. R., Buenaventura, T., Tomás, A., & Rutter, G. A. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.013 · Cited by 107
Incretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93
Murga, C., Arcones, A. C., Cruces‐Sande, M., Briones, A. M., Salaíces, M., & Mayor, F. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00112 · Cited by 100
Cancer Biology and Prevention in Diabetes
Srivastava, S. P., & Goodwin, J. E. (2020) · Cells · doi:10.3390/cells9061380 · Cited by 83
Adipose tissue glycogen accumulation is associated with obesity-linked inflammation in humans
Ceperuelo‐Mallafré, V., Ejarque, M., Serena, C., Durán, X., Montori-Grau, M., Rodriguez, M. A., Yanes, Ó., Núñez‐Roa, C., Roche, K., Puthanveetil, P., et al. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.10.001 · Cited by 83
Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes
Kato, H., Nagai, Y., Ohta, A., Tenjin, A., Nakamura, Y., Tsukiyama, H., Sasaki, Y., Fukuda, H., Ohshige, T., Terashima, Y., et al. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.04.008 · Cited by 70
GIPR Is Predominantly Localized to Nonadipocyte Cell Types Within White Adipose Tissue
Campbell, J. E., Beaudry, J. L., Svendsen, B., Baggio, L. L., Gordon, A. N., Ussher, J. R., Wong, C. K., Gribble, F. M., D’Alessio, D. A., Reimann, F., et al. (2022) · Diabetes · doi:10.2337/db21-1166 · Cited by 68
Yu, X., Chen, S., Funcke, J.-B., Straub, L. G., Pirro, V., Emont, M. P., Droz, B. A., Collins, K. A., Joung, C., Pearson, M. J., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2024.11.003 · Cited by 67
Austregésilo de Athayde De Hollanda Morais, B., Martins Prizão, V., de Moura de Souza, M., Ximenes Mendes, B., Rodrigues Defante, M. L., Cosendey Martins, O., & Rodrigues, A. M. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108834 · Cited by 68
Møller, C. L., Vistisen, D., Færch, K., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Jørgensen, M. E., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3133 · Cited by 62
Asmar, M., Simonsen, L., Asmar, A., Holst, J. J., Dela, F., & Bülow, J. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1933 · Cited by 61
Sánchez‐Tapia, M., Martínez-Medina, J., Tovar, A. R., & Torres, N. (2019) · Nutrients · doi:10.3390/nu11040880 · Cited by 61
Al-Sabah, S., Al-Fulaij, M., Shaaban, G., Ahmed, H. A., Mann, R. J., Donnelly, D., Bünemann, M., & Krasel, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106890 · Cited by 54
Ejarque, M., Guerrero-Pérez, F., de la Morena, N., Casajoana, A., Virgili, N., López-Urdiales, R., Maymó-Masip, E., Pujol Gebelli, J., Garcia Ruiz de Gordejuela, A., Perez-Maraver, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-42770-1 · Cited by 53
Self-citationCeddia, R. P., & Collins, S. (2020) · Clinical Science · doi:10.1042/cs20190579 · Cited by 54
Li, C., Wang, J., Song, K., Meng, J., Xu, F., Li, L., & Zhang, G. (2018) · BMC Genomics · doi:10.1186/s12864-018-4996-z · Cited by 52
Mayor, F., Cruces‐Sande, M., Arcones, A. C., Vila‐Bedmar, R., Briones, A. M., Salaíces, M., & Murga, C. (2017) · Cellular Signalling · doi:10.1016/j.cellsig.2017.04.002 · Cited by 57
Asmar, M., Arngrim, N., Simonsen, L., Asmar, A., Nordby, P., Holst, J. J., & Bülow, J. (2016) · Nutrition & Diabetes · doi:10.1038/nutd.2016.15 · Cited by 42
Maïmoun, L., Guillaume, S., Lefebvre, P., Philibert, P., Bertet, H., Picot, M., Gaspari, L., Paris, F., Sénèque, M., Dupuys, A.-M., et al. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3223-x · Cited by 46
Insights into incretin-based therapies for treatment of diabetic dyslipidemia
Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 43
Hjuler, S. T., Andreassen, K. V., Gydesen, S., Karsdal, M. A., & Henriksen, K. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.05.051 · Cited by 41
GIP-induced vasodilation in human adipose tissue involves capillary recruitment
Asmar, M., Asmar, A., Simonsen, L., Dela, F., Holst, J. J., & Bülow, J. (2019) · Endocrine Connections · doi:10.1530/ec-19-0144 · Cited by 37
Martinez-Perez, B., Ejarque, M., Gutiérrez, C., Núñez‐Roa, C., Roche, K., Vila‐Bedmar, R., Ballesteros, M., Redondo‐Angulo, I., Planavila, A., Villarroya, F., et al. (2016) · Translational research · doi:10.1016/j.trsl.2016.06.012 · Cited by 34
GIP’s involvement in the pathophysiology of type 2 diabetes
Christensen, M. B., Gasbjerg, L. S., Heimbürger, S. M., Stensen, S., Vilsbøll, T., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170178 · Cited by 35
Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases
Liu, J., Ting, J. P., Al-Azzam, S., Ding, Y., & Afshar, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062805 · Cited by 40
Mather, K. J., Mari, A., Heise, T., DeVries, J. H., Hua, M., Urva, S., Coskun, T., Haupt, A., Heine, R. J., Pratt, E., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae319 · Cited by 35
Ejarque, M., Ceperuelo‐Mallafré, V., Serena, C., Pachón, G., Núñez‐Álvarez, Y., Terrón‐Puig, M., Calvo, E., Núñez‐Roa, C., Oliva‐Olivera, W., Tinahones, F. J., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.209 · Cited by 36
Rameshrad, M., Razavi, B. M., Lalau, J., Broe, M. E. D., & Hosseinzadeh, H. (2020) · PubMed Central · doi:10.22038/ijbms.2020.41638.9832 · Cited by 41
Jiang, Y., Zhu, H., & Gong, F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16106 · Cited by 36
Ceperuelo‐Mallafré, V., Ejarque, M., Durán, X., Pachón, G., Vázquez‐Carballo, A., Roche, K., Núñez‐Roa, C., Garrido‐Sánchez, L., Tinahones, F. J., Vendrell, J. J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129644 · Cited by 32
Pelle, M. C., Provenzano, M., Zaffina, I., Pujia, R., Giofrè, F., Lucà, S., Andreucci, M., Sciacqua, A., & Arturi, F. (2021) · Life · doi:10.3390/life12010029 · Cited by 28
Regazzo, D., Barbot, M., Scaroni, C. M., Albiger, N. M. E., & Occhi, G. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09536-6 · Cited by 33
Razny, U., Kiec-Wilk, B., Polus, A., Goralska, J., Malczewska-Malec, M., Wnek, D., Zdzienicka, A., Gruca, A., Childs, C. E., Kapusta, M., et al. (2015) · BBA Clinical · doi:10.1016/j.bbacli.2015.05.001 · Cited by 27
“Therefore, normalisation of GIP/GIP receptor 388 signalling has been suggested as a potential target in the treatment of obesity389 associated type 2 diabetes [57].”
Genetics, genomics, and diet interactions in obesity in the Latin American environment
Guevara‐Ramírez, P., Cadena-Ullauri, S., Ruiz‐Pozo, V. A., Tamayo‐Trujillo, R., Paz‐Cruz, E., Simancas‐Racines, D., & Zambrano, A. K. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1063286 · Cited by 34
Adipose Tissue Hypoxia in Obesity: Clinical Reappraisal of Hypoxia Hypothesis
Engin, A. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-63657-8_11 · Cited by 34
Ejarque, M., Borlaug, M., Vilarrasa, N., Martinez-Perez, B., Llauradó, G., Megía, A., Helland, T., Gutiérrez, C., Serena, C., Folkestad, O. H., et al. (2017) · Translational research · doi:10.1016/j.trsl.2017.03.001 · Cited by 25
Pro-inflammatory gene expression profile in obese adults with high plasma GIP levels
Góralska, J., Raźny, U., Polus, A., Stancel-Możwiłło, J., Chojnacka, M., Gruca, A., Zdzienicka, A., Dembińska-Kieć, A., Kieć-Wilk, B., Solnica, B., et al. (2018) · International Journal of Obesity · doi:10.1038/ijo.2017.305 · Cited by 22
Chen, X., He, X., Guo, Y., Liu, L., Li, H., Tan, J., Feng, W., Guan, H., Cao, X., Xiao, H., et al. (2021) · The FASEB Journal · doi:10.1096/fj.201903253r · Cited by 22
Beaudry, J. L., & Drucker, D. J. (2019) · Endocrinology · doi:10.1210/endocr/bqz029 · Cited by 24
Spleen volume on CT and the effect of abdominal trauma
Cruz‐Romero, C., Agarwal, S., Abujudeh, H. H., Thrall, J. H., & Hahn, P. F. (2016) · Emergency Radiology · doi:10.1007/s10140-016-1402-5 · Cited by 20
van Eenige, R., Ying, Z., Tramper, N., Wiebing, V., Siraj, Z., de Boer, J. F., Lambooij, J. M., Guigas, B., Qu, H., Coşkun, T., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.03.016 · Cited by 20
Pharmacological modulation of adaptive thermogenesis: new clues for obesity management?
Genchi, V. A., Palma, G., Sorice, G. P., D’Oria, R., Caccioppoli, C., Marrano, N., Biondi, G., Caruso, I., Cignarelli, A., Natalicchio, A., et al. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02125-0 · Cited by 23
Common variants of GIP are associated with visceral fat accumulation in Japanese adults
Nakayama, K., Watanabe, K., Boonvisut, S., Makishima, S., Miyashita, H., & Iwamoto, S. (2014) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00282.2014 · Cited by 19
Oshima, N., Onimaru, H., Matsubara, H., Uchida, T., Watanabe, A., Imakiire, T., Nishida, Y., & Kumagai, H. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2016.12.039 · Cited by 18
De Fano, M., Malara, M., Vermigli, C., & Murdolo, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168650 · Cited by 17
Reed, J., Bain, S. C., & Kanamarlapudi, V. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s415934 · Cited by 24
Ajabnoor, G., Hashim, K. T., Alzahrani, M. M., Alsuheili, A. Z., Alharbi, A. F., Alhozali, A. M., Enani, S. M., Eldakhakhny, B. M., & Elsamanoudy, A. Z. (2023) · Diseases · doi:10.3390/diseases11010050 · Cited by 20
Mahri, S. A., Okla, M., Rashid, M., Malik, S. S., Iqbal, J., Ibrahim, M. A., Dairi, G., Mahmood, A., Manikandan, M., Yaqinuddin, A., et al. (2023) · Cells · doi:10.3390/cells12030377 · Cited by 16
Sakane, N., Osaki, N., Takase, H., Suzuki, J. S., Suzukamo, C., Nirengi, S., Suganuma, A., & Shimotoyodome, A. (2019) · Nutrition Journal · doi:10.1186/s12937-019-0472-0 · Cited by 17
Tharp, W. G., Gupta, D., Sideleva, O., Deacon, C. F., Holst, J. J., Elahi, D., & Pratley, R. E. (2019) · Diabetes · doi:10.2337/db18-1163 · Cited by 16
GIPR Agonism Enhances TZD-Induced Insulin Sensitivity in Obese IR Mice
Furber, E. C., Hyatt, K., Collins, K. A. L., Yu, X., Droz, B. A., Holland, A. K., Friedrich, J. L., Wojnicki, S., Konkol, D. L., O’Farrell, L. S., et al. (2023) · Diabetes · doi:10.2337/db23-0172 · Cited by 17
English, A. R., Craig, S. L., Flatt, P. R., & Irwin, N. (2020) · Biological Chemistry · doi:10.1515/hsz-2020-0195 · Cited by 14
Thazhath, S. S., Wu, T., Bound, M. J., Checklin, H. L., Standfield, S., Jones, K. L., Horowitz, M., & Rayner, C. K. (2015) · Nutrition · doi:10.1016/j.nut.2015.11.004 · Cited by 14
A Mechanistic Rationale for Incretin-Based Therapeutics in the Management of Obesity
Samms, R. J., & Kusminski, C. M. (2024) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022724-105443 · Cited by 12
Guaita-Céspedes, M., Grillo-Risco, R., Hidalgo, M. R., Fernández‐Veledo, S., Burks, D. J., de la Iglesia-Vayá, M., Galán, A., & Garcia‐García, F. (2023) · Biology of Sex Differences · doi:10.1186/s13293-023-00506-x · Cited by 11
Rieger, T. R., & Musante, C. J. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.05.006 · Cited by 10
Dorajoo, R., Ong, R.-H., Sim, X., Wang, L., Liu, W., Tai, E. S., Liu, J., & Saw, S. (2016) · Pediatric Obesity · doi:10.1111/ijpo.12175 · Cited by 11
The color of fat and its central role in the development and progression of metabolic diseases
Gaggini, M., Carli, F., & Gastaldelli, A. (2017) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2017-0060 · Cited by 12
Suh, S., Kim, M. Y., Kim, S. K., Hur, K. Y., Park, M. K., Kim, D. K., Cho, N. H., & Lee, M. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.1.134 · Cited by 11
Kheder, M. H., Sillence, M. N., Bryant, L. M., & de Laat, M. A. (2017) · Journal of Animal Science · doi:10.2527/jas.2017.1468 · Cited by 12
Brachs, S., Soll, D., Beer, F., Huckauf, N., Konkar, A. A., Spranger, J., Rütten, H., & Mai, K. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae151 · Cited by 7
The GIPR is Predominantly Localized to Non-Adipocyte Cell Types Within White Adipose Tissue
Campbell, J. E., Beaudry, J. L., Svendsen, B., Baggio, L. L., Gordon, A. N., Ussher, J. R., Wong, C. K., Gribble, F. M., D’Alessio, D. A., Reimann, F., et al. (2022) · doi:10.2337/figshare.19184462 · Cited by 6
Nogare, M. D., D’Annunzio, S., Vazza, G., Regazzo, D., Picello, L., Denaro, L., Voltan, G., Scaroni, C. M., Ceccato, F., & Occhi, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119264 · Cited by 6
The effect and application of adiponectin in hepatic fibrosis
Chen, T., Yang, W., Dong, R., Yao, H., Sun, M., Wang, J., Zhou, Q. G., & Xu, J. (2023) · Gastroenterology report · doi:10.1093/gastro/goae108 · Cited by 8
Targeting cardiometabolic risk in type 1 diabetes through incretin physiology
Frampton, R., HOCKING, S. L., SNAITH, J. R., & Greenfield, J. R. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.06.004 · Cited by 4
Cataldi, S., Aprile, M., Perfetto, C., Angot, B., Cormont, M., Ciccodicola, A., Tanti, J., & Costa, V. (2023) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2023.151320 · Cited by 4
Babenko, A. Y., Matveev, G. A., Алексеенко, Т. И., Derevitskii, I. V., Kokina, M. A., & Shlyakhto, E. V. (2020) · Arterial’naya Gipertenziya (Arterial Hypertension) · doi:10.18705/1607-419x-2019-25-6-639-652 · Cited by 6
Skuratovskaia, D., Vulf, M. A., Кириенкова, Е. В., Mironyuk, N. I., Затолокин, П. А., & Litvinova, L. S. (2018) · Biomeditsinskaya Khimiya · doi:10.18097/pbmc20186402208 · Cited by 4
Gut Hormones and Inflammatory Bowel Disease
Weng, J., & Lo, C. C. (2025) · Biomolecules · doi:10.3390/biom15071013 · Cited by 7
Anti-obesity effects of galla rhois via genetic regulation of adipogenesis
Yi, S. H., Jeong, Y. J., Jeon, H., Park, J.-H., Kim, I., Her, Y., Kwon, J. E., Shin, H.-S., & Kang, S. C. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112063 · Cited by 3
Jia, X., Wang, A., Yang, L., Cheng, Y., Wang, Y., Ba, J., Dou, J., Mu, Y., Zhao, D., & Lyu, Z. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.839195 · Cited by 3
Dulaglutide use to improve binge eating behaviors in a person with type 2 diabetes and obesity
Innocent, B., Elmaoued, A. A., Cowart, K., & White, R. T. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf088 · Cited by 5
Chen, J., Zheng, S., Hu, Y., Mou, X., & Wang, H. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119038 · Cited by 4
RetractedRevitalizing GIP: Therapeutic Potential in Metabolic and Neurodegenerative Disorders
Qiao, Y., Zhou, F., Mao, T., & Gao, L. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s559587 · Cited by 4
Research advances in understanding crosstalk between organs and pancreatic β‐cell dysfunction
Huang, P., Zhu, Y., & Qin, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15787 · Cited by 3
Yamamoto, Y., Ozamoto, Y., Kobayashi, M., Tezuka, Y., Azuma, C., Sekine, O., Ito-Kobayashi, J., Washiyama, M., Oe, Y., Iwanishi, M., et al. (2022) · Endocrine Journal · doi:10.1507/endocrj.ej21-0615 · Cited by 2
Mattos, A. M. D. S., Costa, S. C., Outuki, G., Koga, G. K. C., Montemor, C. N., Longo, G. Z., Watanabe, M. A. E., Amarante, M. K., & Mazzuco, T. L. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/340539 · Cited by 2
Das, S., Ravi, H., Babu, A., Banerjee, M., Ramasubbu, K., Sivaraman, D., Rajeswari, V. D., Venkatraman, G., & Ramanathan, G. (2024) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2023.12.017 · Cited by 1
Palanichamy, C., Pavadai, P., Theivendren, P., Murugesan, S., Sundar, M., & Kunjiappan, S. (2025) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-025-10064-x · Cited by 1
Xie, T., Zhao, L., Pei, S., Wen, K., Fei, S., Chen, W., Li, Z., Zhang, L., Li, L., Guo, L., et al. (2025) · Small Science · doi:10.1002/smsc.202500300 · Cited by 1
Skuratovskaia, D., Vulf, M. A., Кириенкова, Е. В., Mironyuk, N. I., Затолокин, П. А., & Litvinova, L. S. (2018) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s1990750818030071 · Cited by 1
Kheder, M. H. (2018) · Queensland University of Technology · doi:10.5204/thesis.eprints.122879 · Cited by 1
ASSOCIATION BETWEEN GIP GENE POLYMORPHISM AND OBESE ADULTS IN BABYLON GOVERNORATE, IRAQ
Kamal, A., & Hassan, H. A. J. (2016) · International Journal of Pharma and Bio Sciences
Guaita-Céspedes, M., Grillo-Risco, R., Hidalgo, M. R., Fernández‐Veledo, S., Gómez-Cabañes, B., Anton-Bernat, G., Gómez-Martínez, H., Burks, D. J., de la Iglesia-Vayá, M., Galán, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.04.471124
Guaita-Céspedes, M., Grillo-Risco, R., Hidalgo, M. R., Fernández‐Veledo, S., Burks, D. J., de la Iglesia-Vayá, M., Galán, A., & Garcia‐García, F. (2022) · Research Square · doi:10.21203/rs.3.rs-1847531/v1
The obesity-linked peptide SP16 regulates adipocytes through GIP and insulin receptorPreprint
Ngo, T. M. H., Santhanam, R., Teufel, D. P., Dick, A., Lam, D. D., Klein, H., Brunner, A., Pereira, M. M. A., Bartelt, A., Pekcec, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.17.660082
Metadata
- Authors
- Ceperuelo-Mallafré, V., Duran, X., Pachón, G., Roche, K., Garrido-Sánchez, L., Vilarrasa, N., Tinahones, F. J., Vicente, V., Pujol, J., Vendrell, J., & Fernández-Veledo, S.
- Affiliations
- CIBER de Fisiopatología de la Obesidad y la Nutrición (CIBERobn-Instituto de Salud Carlos III, 28029 Madrid, Spain) and Hospital Universitario Virgen de la Victoria (V.C.-M., L.G.-S., F.J.T.), 29010 Málaga, Spain
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM-Instituto de Salud Carlos III, 28029 Madrid, Spain) (X.D., G.P., K.R., N.V., J.V., S.F.-V.), 43007 Tarragona, Spain
- Instituto de Salud Carlos III (ES)
- Institut de Recerca Biomèdica Catalunya Sud (ES)
- Bellvitge University Hospital (ES)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2014-05-01
- Volume
- 99
- Issue
- 5
- Pages
- E908-E919
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2024751668
- Cited by
- 112
- References
- 39
- Citations by year
- 2026: 8 · 2025: 8 · 2024: 13 · 2023: 13 · 2022: 7 · 2021: 7 · 2020: 10 · 2019: 9 · 2018: 7 · 2017: 9 · 2016: 10 · 2015: 9 · 2014: 2
- FWCI
- 7.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Funders
- Ministerio de Economía y Competitividad (PI12/, SAF2012, SAF2012-36186)
- Universität Ulm
- European Regional Development Fund (PI11/0085, SAF2012-36186)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- glucose-dependent insulinotropic polypeptide, GIP receptor, obesity, insulin resistance, subcutaneous adipose tissue, visceral adipose tissue, GRK2, IRS-1, hypoxia, adipocytes, adipose-derived stem cells, dipeptidyl peptidase IV, incretins, insulin sensitivity, glucose uptake
- MeSH terms
- Adipose Tissue, Adult, Aged, Cell Line, Female, Gastric Inhibitory Polypeptide, Humans, Insulin Resistance, Male, Middle Aged, Obesity, Receptors, Gastrointestinal Hormone, Signal Transduction, Down-Regulation, Body Mass Index, Adipocytes, Waist Circumference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.